Related Experiment Video
Updated: Jul 15, 2026

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
Published on: April 11, 2025
Biventricular pacing and QT interval prolongation
Atul Bhatia1, Vikram Nangia, Joaquin Solis
1Electrophysiology Laboratories of Aurora Sinai/St. Luke's Medical Centers, University of Wisconsin Medical School-Milwaukee Clinical Campus, Milwaukee, Wisconsin, USA. bdanek@hrtcare.com
Insights
Biventricular pacing in heart failure patients prolongs the QT interval, potentially increasing arrhythmia risk. However, serious arrhythmias like torsade de pointes remain uncommon with this therapy.
Area of Science:
- Cardiology
- Electrophysiology
- Heart Failure Management
Background:
- Biventricular pacing (BiV) is a key therapy for advanced congestive heart failure (CHF) and bundle branch block (BBB).
- Understanding BiV pacing's effects on cardiac electrophysiology is crucial for patient safety.
- The potential for proarrhythmia, particularly QT interval prolongation, requires investigation.
Purpose of the Study:
- To assess changes in QT interval duration due to BiV pacing.
- To evaluate the risk of proarrhythmia associated with BiV pacing in CHF patients.
Main Methods:
- Studied 176 patients with ischemic or non-ischemic cardiomyopathy (NYHA Class II/III CHF).
- Patients underwent atrial synchronous BiV pacing.
- QRS, QT, and JT intervals were measured at baseline, 30 minutes, 24 hours, and 1 month post-implant.
Main Results:
- BiV pacing significantly reduced QRS duration (148 ms vs. 178 ms).
- BiV pacing significantly prolonged the QT interval (470 ms vs. 445 ms).
- One patient experienced torsade de pointes, which resolved upon discontinuation of left ventricular pacing.
Conclusions:
- Biventricular pacing leads to a significant prolongation of the QT interval.
- Despite QT prolongation, the incidence of torsade de pointes is infrequent in patients undergoing BiV pacing.
Introduction:
The purpose of this study was to examine BiV pacing-dependent changes in QT interval and the related potential for proarrhythmia. Biventricular (BiV) pacing has emerged as a promising therapy for patients with advanced congestive heart failure (CHF) and bundle branch block (BBB).
Methods And Results:
One hundred and seventy-six consecutive patients (123 men and 53 women; mean age 67 +/- 16 years) with ischemic (n = 128) or nonischemic (n = 48) cardiomyopathy in New York Heart Association Class II (8%) or III (92%) CHF (ejection fraction 24 +/- 9%) underwent atrial synchronous BiV pacing. The QRS, QT, and JT intervals were measured at 30 minutes after initiation of BiV pacing, at 24 hours, and at 1 month postimplant. QT interval was defined as the time interval between the initial deflection of the QRS complex and the point at which the T wave crossed the isoelectric line. At baseline, the average QRS duration was 178 +/- 10 ms, attributable to left BBB (n = 158) or intraventricular conduction delay (n = 18). BiV pacing resulted in a small but statistically significant reduction in QRS duration (148 +/- 9 ms during BiV pacing vs 178 +/- 10 ms at baseline [P < 0.0001]), yet the QT increased to 470 +/- 34 ms with BiV pacing versus 445 +/- 32 ms at baseline [P < 0.0001]). The JTc interval during BiV pacing was significantly shorter than during LV pacing (290 +/- 9 ms vs 320 +/- 20 ms, P < 0.0001). During a mean follow-up of 24 +/- 6 months, one patient developed recurrent torsade de pointes. That was eliminated once left ventricular pacing was discontinued.
Conclusion:
Biventricular pacing prolongs QT interval. However, the occurrence of torsade de pointes is uncommon.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
08:05Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
Published on: June 29, 2022
Related Concept Videos
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Dysrhythmias IV: Characteristics of Bradyarrhythmias
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers